Scholar Rock's stock rises after FDA approves isembyld for spinal muscular atrophy
Scholar Rock Holding (SRRK) saw its shares rise by 12% in extended trading following the U.S. Food and Drug Administration’s approval of its drug, isembyld, for treating spinal muscular atrophy. The FDA approved isembyld—also known as apitegromab-mstn—for use in adults and children aged two years or older who have this genetic disorder. The treatment targets a protein involved in muscle wasting, offering new therapeutic options for patients with limited alternatives. This regulatory milestone marks a significant development for Scholar Rock, potentially opening up revenue streams from the commercialization of isembyld while enhancing its market position and investor confidence.
Tickers: $SRRK
Topics: drug approval pharmaceuticals spinal muscular atrophy